CA
NZ
UK
AU
IND
US
Incyte Corporation (NASDAQ: INCY) is scheduled to present two separate Phase 3 oncology readouts at the ESMO 2026 congress, covering candidates in pancreatic cancer and ovarian cancer.
Kalaris Therapeutics (NASDAQ: KLRS) presented Phase 1a data at the ASRS meeting on July 17, 2026, showing significant gains in visual acuity and retinal thickness for its neovascular age-related macular degeneration candidate, TH103.
Veradermics Incorporated (NASDAQ: MANE) shares closed up 5.19% at $111.32 after the company shared Phase 2/3 data for its male pattern hair loss candidate VDPHL01 at the AAD Innovation Academy on July 17, 2026.
Isoray (NASDAQ: CATX) is scheduled to present Phase 1 data covering cohorts 1 through 3 for its radiopharmaceutical candidate [212Pb]VMT-α-NET in neuroendocrine tumors at the ESMO 2026 congress on October 23.
Agenus Inc. (NASDAQ: AGEN) is scheduled to present Phase 2 results from its NEOASIS study of neoadjuvant BOT/BAL in MMR-deficient colorectal cancer at the ESMO 2026 congress on October 25.
IDEAYA Biosciences (NASDAQ: IDYA) is scheduled to present first Phase 1 data for IDE849, also known as SHR-4849, in solid tumors and small cell lung cancer at the ESMO 2026 congress, running October 23-27.
Merck & Company (NYSE: MRK) is set to present three-year Phase 2 data on its personalized cancer vaccine EVX-01, used in combination with KEYTRUDA (pembrolizumab) and OPDIVO (nivolumab), at the ESMO 2026 congress running October 23-27.
Compass Therapeutics (NASDAQ: CMPX) is scheduled to present Phase 2/3 results from a randomized controlled trial of CTX-009, a DLL4 x VEGF-A bispecific antibody, in biliary tract cancer at the ESMO 2026 congress on October 24.
Immatics N.V. (NASDAQ: IMTX) is scheduled to provide a Phase 1/2 clinical data update on IMA402 in solid tumors at the ESMO 2026 congress on October 24.
Trevi Therapeutics (NASDAQ: TRVI) shares closed up 10% at $19.07 after the company announced its leadership team will participate in a series of upcoming industry events centered on its lead candidate, Haduvio.
Please wait processing your request...